PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Barbara Wirostko, Altheos – Presents at 3rd Ocular Diseases & Drug Discovery Conference Boston, MA - Barbara Wirostko, Chief Medical Officer of Altheos will give a featured presentation at GTCbio’s 3rd Ocular Disease & Drug Discovery Conference, May 26-27, in Boston, MA
Barbara Wirostko, Altheos – Presents at 3rd Ocular Diseases & Drug Discovery Conference Boston, MA

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2011/03/03 - Barbara Wirostko, Chief Medical Officer of Altheos will give a featured presentation at GTCbio’s 3rd Ocular Disease & Drug Discovery Conference, May 26-27, in Boston, MA.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Barbara Wirostko, M.D., Chief Medical Officer, Altheos, will give a featured presentation on Rho Kinase Inhibitors for Glaucoma: IOP Lowering Plus at GTC’s 3rd Ocular Diseases & Drug Discovery Conference on May 26-27, 2011 in Boston, MA.

Barbara Wirostko will present her topic on glaucoma treatment, discussing how Rho kinase (ROCK1 and ROCK2) is a serine/threonine kinase that serves as an important downstream effector of Rho GTPase. This class of kinases plays a key role in regulating the contractile tone of smooth muscle tissue through actin stress fibers via the phosphorylation of MLC (myosin light chain) in a calcium-independent manner. Myosin phosphorylation and the resultant increase in the contractile state is regulated through ROCK and subsequent vascular smooth muscle mediators such as Nitric oxide and endothelin. Rock inhibition leads to the relaxation of smooth muscle fibers. Experimental evidence indicates that inhibiting ROCK activity through topical and systemic ROCK I s could be beneficial for the treatment of increased intraocular pressure in patients with glaucoma. The rationale stems from data suggesting that both ROCK and Rho GTPase inhibitors can increase aqueous humor drainage via trabecular meshwork smooth muscle and ciliary muscle relaxation.

GTC’s 3rd Ocular Diseases conference will also bring together leaders from GlaxoSmithKline, ORA, the John A. Moran Eye Center, Santen, Allergan, and more. Updates on age-related macular degeneration, recent drug developments and mechanisms, rho kinase inhibitors, and the future of ocular disease therapeutics will be addressed and discussed.

GTCbio’s 3rd Ocular Disease & Drug Discovery Conference will provide cutting edge information and a chance to exchange ideas from leading experts in the field.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Barbara Wirostko, Altheos – Presents at 3rd Ocular Diseases & Drug Discovery Conference Boston, MA

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  MagLar, Inc.

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)